Overview

Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test

Status:
Completed

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

To evaluate the early (3-month) impact of the long-acting anticholinergic Spiriva HH maintenance treatment on the COPD symptoms using the novel COPD Assessment test (CAT) in the real life setting of COPD patients, previously treated with short-acting bronchodilator on regular or as-needed basis.

Phase:

Phase 4

Details

Lead Sponsor:

Boehringer Ingelheim

Collaborator:

Pfizer

Treatments:

Tiotropium Bromide